Whitepapers

May 01, 2017
Sponsored Content
The ongoing advances in cancer immunotherapy together with precision medicine may promise a bright future for patients. Learn about the two most common biomarkers in clinical trials that are critical for the drug development process.
Apr 29, 2017
Sponsored Content
In our rapidly changing healthcare system, the importance of PAs and NPs continues to grow in step with their increased contribution to patient care. Are you including these healthcare providers in your brand strategy? If not, we share compelling reasons why you should and targeted tips to get you started.
Apr 25, 2017
Sponsored Content
Protein-based science will account for more than 25% of the bio-pharma global portfolio in the very near future. At the same time the shift in pharmaceutical manufacturing to more predictive and adaptive plants will aim to better serve patients , which leverage modular technology (POD), disposable components, Internet of Things, smart objects, remote control and augment reality The landscape for Biopharmaceutical manufacturing is rapidly changing with the shift toward large molecule and biosimilars manufacture of therapeutic solutions to address patients’ changing needs, while at the same time confronting the significant responsibility of always providing consistent product quality and efficacy independent of where they are produced.
Apr 19, 2017
Sponsored Content
The approval of novel orphan drug designations continues to grow, while many existing rare disease therapies are receiving approval for expanded indications. With this increase Rare Disease Drug Development and broadening class of products, including some that target the same mutation or molecular defect, sponsors face new and significant market access challenges in securing reimbursement.
Apr 01, 2017
Sponsored Content
Pharmaceutical brand marketers consistently face two challenges in structuring their sales forces – penetrating hard to reach whitespace territories, and maintaining prescriptions in vacant territories during the time they are uncovered. Successfully addressing these two concerns can be the difference between driving increased brand performance and simply maintaining the status quo or worse, losing market share to competitors.
Apr 01, 2017
Sponsored Content
In the life sciences realm, “Big Data” is not a buzzword; it’s an opportunity to improve efficiency, product effectiveness, and financial outcomes. In this article, hear from LexisNexis Health Care experts about why they believe Big Data can turn needs into opportunities for massive growth and unprecedented success at all levels. Also, hear about some innovative new tools that are breaking new ground in the pharmaceuticals, biotechnology and medical devices industries.
Mar 24, 2017
Sponsored Content
Deloitte’s 2017 Real-World Evidence Benchmark Survey shows that life sciences companies are making some progress in using RWE but still have opportunities to expand applications across the value chain, consider new channels to access RWD, and improve their overall capabilities.
Mar 01, 2017
Sponsored Content
To succeed in today’s complex IDN market, life sciences organizations can leverage innovative data insights and analytics intelligence to increase commercial efficiency and effectiveness. Download the Case Study to learn how.
Nov 02, 2016
Sponsored Content
Read this guide to learn how to improve quality oversight for your global pharmaceutical company, including: • Five steps to aligning quality at your organization • Practical recommendations to improve collaboration • Ways to balance global and local needs • Common mistakes in quality harmonization initiatives
Oct 27, 2016
Sponsored Content
By AHM
Despite the Open Payments Program, HCPs continue to support interactions with Life Sciences companies. Learn what HCPs value when participating in promotional programs and why they continue to support these interactions.
native1_300x100
lorem ipsum